MetaVia (MTVA) Competitors $0.68 +0.02 (+2.47%) As of 12:45 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsTrendsBuy This Stock MTVA vs. APLT, IPSC, AVTX, KRON, ANVS, VTVT, ZIVO, ADVM, RENB, and ALGSShould you be buying MetaVia stock or one of its competitors? The main competitors of MetaVia include Applied Therapeutics (APLT), Century Therapeutics (IPSC), Avalo Therapeutics (AVTX), Kronos Bio (KRON), Annovis Bio (ANVS), vTv Therapeutics (VTVT), ZIVO Bioscience (ZIVO), Adverum Biotechnologies (ADVM), Renovaro (RENB), and Aligos Therapeutics (ALGS). These companies are all part of the "pharmaceutical products" industry. MetaVia vs. Its Competitors Applied Therapeutics Century Therapeutics Avalo Therapeutics Kronos Bio Annovis Bio vTv Therapeutics ZIVO Bioscience Adverum Biotechnologies Renovaro Aligos Therapeutics Applied Therapeutics (NASDAQ:APLT) and MetaVia (NASDAQ:MTVA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk. Do analysts prefer APLT or MTVA? Applied Therapeutics currently has a consensus target price of $6.10, indicating a potential upside of 1,342.08%. MetaVia has a consensus target price of $7.50, indicating a potential upside of 996.49%. Given Applied Therapeutics' higher possible upside, equities research analysts clearly believe Applied Therapeutics is more favorable than MetaVia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Applied Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50MetaVia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings and valuation, APLT or MTVA? MetaVia has lower revenue, but higher earnings than Applied Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApplied Therapeutics$265K225.99-$105.62M-$0.43-0.98MetaViaN/AN/A-$27.59MN/AN/A Does the media prefer APLT or MTVA? In the previous week, MetaVia had 2 more articles in the media than Applied Therapeutics. MarketBeat recorded 3 mentions for MetaVia and 1 mentions for Applied Therapeutics. Applied Therapeutics' average media sentiment score of 1.87 beat MetaVia's score of -0.13 indicating that Applied Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Applied Therapeutics Very Positive MetaVia Neutral Do insiders & institutionals believe in APLT or MTVA? 98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 1.4% of MetaVia shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by company insiders. Comparatively, 0.8% of MetaVia shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is APLT or MTVA more profitable? Applied Therapeutics' return on equity of -184.67% beat MetaVia's return on equity.Company Net Margins Return on Equity Return on Assets Applied TherapeuticsN/A -184.67% -84.02% MetaVia N/A -222.13%-123.85% Which has more volatility & risk, APLT or MTVA? Applied Therapeutics has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500. Comparatively, MetaVia has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500. SummaryApplied Therapeutics beats MetaVia on 9 of the 12 factors compared between the two stocks. Get MetaVia News Delivered to You Automatically Sign up to receive the latest news and ratings for MTVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTVA vs. The Competition Export to ExcelMetricMetaViaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.40M$2.92B$5.56B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E RatioN/A20.3528.6119.64Price / SalesN/A304.32437.49188.30Price / CashN/A43.1536.0257.93Price / Book0.747.718.185.63Net Income-$27.59M-$55.11M$3.23B$257.73M7 Day Performance-1.01%0.68%-0.25%0.07%1 Month Performance-6.19%8.22%5.40%8.32%1 Year PerformanceN/A-2.64%26.35%13.78% MetaVia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTVAMetaVia1.7182 of 5 stars$0.68+2.5%$7.50+996.5%N/A$13.40MN/A0.008APLTApplied Therapeutics4.5359 of 5 stars$0.38+4.1%$6.10+1,488.5%-92.9%$54.37M$460K-0.8930Positive NewsGap UpIPSCCentury Therapeutics3.2429 of 5 stars$0.63+11.5%$4.20+569.9%-79.0%$54.02M$6.59M-2.16170News CoverageAVTXAvalo Therapeutics3.1241 of 5 stars$4.97+2.4%$30.00+504.2%-60.8%$53.77M$440K0.0040KRONKronos Bio2.4278 of 5 stars$0.88+1.5%$1.63+84.7%-38.9%$53.72M$9.85M-0.82100ANVSAnnovis Bio1.5568 of 5 stars$2.76+8.9%$18.00+553.4%-78.6%$53.71MN/A-1.283VTVTvTv Therapeutics1.6041 of 5 stars$16.78+4.8%$35.50+111.6%-30.8%$53.29M$1.02M-5.559Positive NewsZIVOZIVO BioscienceN/A$13.94+7.2%N/A+57.0%$53.21M$15.85K-2.8610ADVMAdverum Biotechnologies4.397 of 5 stars$2.54+5.6%$23.80+838.9%-69.7%$52.75M$1M-0.39190News CoverageRENBRenovaro1.8761 of 5 stars$0.30-0.9%N/A-80.0%$52.15MN/A-0.3920ALGSAligos Therapeutics4.1442 of 5 stars$8.63+4.7%$70.00+711.1%-33.3%$52.11M$3.94M-0.4990 Related Companies and Tools Related Companies APLT Alternatives IPSC Alternatives AVTX Alternatives KRON Alternatives ANVS Alternatives VTVT Alternatives ZIVO Alternatives ADVM Alternatives RENB Alternatives ALGS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTVA) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MetaVia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MetaVia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
